-
Je něco špatně v tomto záznamu ?
Biological hypotheses, risk factors, and biomarkers of schizophrenia
Z. Fišar
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, přehledy, práce podpořená grantem
- MeSH
- antipsychotika * terapeutické užití MeSH
- biologické markery MeSH
- lidé MeSH
- psychotické poruchy * farmakoterapie MeSH
- rizikové faktory MeSH
- schizofrenie * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Both the discovery of biomarkers of schizophrenia and the verification of biological hypotheses of schizophrenia are an essential part of the process of understanding the etiology of this mental disorder. Schizophrenia has long been considered a neurodevelopmental disease whose symptoms are caused by impaired synaptic signal transduction and brain neuroplasticity. Both the onset and chronic course of schizophrenia are associated with risk factors-induced disruption of brain function and the establishment of a new homeostatic setpoint characterized by biomarkers. Different risk factors and biomarkers can converge to the same symptoms of schizophrenia, suggesting that the primary cause of the disease can be highly individual. Schizophrenia-related biomarkers include measurable biochemical changes induced by stress (elevated allostatic load), mitochondrial dysfunction, neuroinflammation, oxidative and nitrosative stress, and circadian rhythm disturbances. Here is a summary of selected valid biological hypotheses of schizophrenia formulated based on risk factors and biomarkers, neurodevelopment, neuroplasticity, brain chemistry, and antipsychotic medication. The integrative neurodevelopmental-vulnerability-neurochemical model is based on current knowledge of the neurobiology of the onset and progression of the disease and the effects of antipsychotics and psychotomimetics and reflects the complex and multifactorial nature of schizophrenia.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22031995
- 003
- CZ-PrNML
- 005
- 20230131151548.0
- 007
- ta
- 008
- 230120s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.pnpbp.2022.110626 $2 doi
- 035 __
- $a (PubMed)36055561
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Fišar, Zdeněk $u Charles University and General University Hospital in Prague, First Faculty of Medicine, Department of Psychiatry, Czech Republic. Electronic address: zfisar@lf1.cuni.cz
- 245 10
- $a Biological hypotheses, risk factors, and biomarkers of schizophrenia / $c Z. Fišar
- 520 9_
- $a Both the discovery of biomarkers of schizophrenia and the verification of biological hypotheses of schizophrenia are an essential part of the process of understanding the etiology of this mental disorder. Schizophrenia has long been considered a neurodevelopmental disease whose symptoms are caused by impaired synaptic signal transduction and brain neuroplasticity. Both the onset and chronic course of schizophrenia are associated with risk factors-induced disruption of brain function and the establishment of a new homeostatic setpoint characterized by biomarkers. Different risk factors and biomarkers can converge to the same symptoms of schizophrenia, suggesting that the primary cause of the disease can be highly individual. Schizophrenia-related biomarkers include measurable biochemical changes induced by stress (elevated allostatic load), mitochondrial dysfunction, neuroinflammation, oxidative and nitrosative stress, and circadian rhythm disturbances. Here is a summary of selected valid biological hypotheses of schizophrenia formulated based on risk factors and biomarkers, neurodevelopment, neuroplasticity, brain chemistry, and antipsychotic medication. The integrative neurodevelopmental-vulnerability-neurochemical model is based on current knowledge of the neurobiology of the onset and progression of the disease and the effects of antipsychotics and psychotomimetics and reflects the complex and multifactorial nature of schizophrenia.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a schizofrenie $x farmakoterapie $7 D012559
- 650 12
- $a antipsychotika $x terapeutické užití $7 D014150
- 650 12
- $a psychotické poruchy $x farmakoterapie $7 D011618
- 650 _2
- $a biologické markery $7 D015415
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 655 _2
- $a práce podpořená grantem $7 D013485
- 773 0_
- $w MED00003930 $t Progress in neuro-psychopharmacology & biological psychiatry $x 1878-4216 $g Roč. 120, č. - (2023), s. 110626
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36055561 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151544 $b ABA008
- 999 __
- $a ok $b bmc $g 1891025 $s 1183330
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 120 $c - $d 110626 $e 20220831 $i 1878-4216 $m Progress in neuro-psychopharmacology & biological psychiatry $n Prog Neuropsychopharmacol Biol Psychiatry $x MED00003930
- LZP __
- $a Pubmed-20230120